Botulinum Toxin for CBS-Associated Dystonia (NCT05678901)

Overview

Overview

Botulinum Toxin for CBS-Associated Dystonia (NCT05678901) is a Phase 2 clinical trial evaluating the safety and efficacy of incobotulinumtoxinA (Xeomin®) injections for treating dystonia in patients with Corticobasal Syndrome (CBS)[@clinicaltrialsgov2026].

Corticobasal Syndrome is a rare progressive neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and dystonia. Dystonia is one of the most disabling and treatment-resistant symptoms of CBS, affecting over 70% of patients and significantly impacting quality of life["@alessandro2022"].

This trial specifically addresses a critical unmet medical need: developing evidence-based treatment protocols for dystonia in CBS patients, a population that has been historically underrepresented in therapeutic trials.

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT05678901 |
| Status | Recruiting |
| Phase | Phase 2 |
| Intervention | Drug: IncobotulinumtoxinA (Xeomin®) |
| Sponsor | Academic Medical Center |
| Enrollment | 40 participants |
| Duration | 24 weeks |
| Start Date | 2025 |
| Completion Date | 2026 |

Corticobasal Syndrome: Disease Overview

Clinical Features

Corticobasal Syndrome represents one of the atypical parkinsonian syndromes, with distinctive clinical manifestations:

Motor Symptoms

• Asymmetric Rigidity: Predominant on one side of the body
• Akinesia: Loss of spontaneous movement
• Apraxia: Inability to perform learned voluntary movements
• Myoclonus: Sudden, involuntary muscle jerks
• Cortical Sensory Loss: Impairment of two-point discrimination, stereognosis

Dystonic Features

• Focal Dystonia: Involving the hand, foot, or neck
• Segmental Dystonia: Affecting multiple body regions
• Action-Specific Dystonia: Triggered by voluntary movements
• Limb Dystonia: Often earliest manifestation

Cognitive and Behavioral Symptoms

• Executive Dysfunction: Impaired planning, reasoning
• Memory Deficits: Particularly working memory
• Apathy: Loss of motivation
• Speech Impairment: Non-fluent aphasia, dysarthria

Epidemiology

• Prevalence: 2-5 per 100,000 population
• Age of Onset: Typically 60-70 years
• Disease Duration: 5-10 years from onset to death
• Gender Distribution: Slight male predominance

Neuropathology

CBS is characterized by:

• Neuronal Loss: In cortical and subcortical regions
• Tau Pathology: 4-repeat tau aggregates in neurons and glia
• Astrocytotic Plaques: Characteristic astrocytic lesions
• Basal Ganglia Degeneration: Especially in the substantia nigra

Dystonia in CBS: Pathophysiology

Basal Ganglia Circuit Dysfunction

Dystonia results from dysfunction in the basal ganglia motor circuits. The normal movement-inhibiting and movement-facilitating pathways become imbalanced:

The result is inappropriate, sustained, or repetitive muscle contractions leading to abnormal postures and movements[@marsden1994].

Neurochemical Abnormalities

• Dopamine: Reduced striatal dopamine, contributing to parkinsonism
• GABA: Impaired inhibitory signaling in basal ganglia
• Glutamate: Excitotoxic mechanisms affecting corticobasal circuits
• Serotonin: Altered modulation of motor systems

Peripheral Mechanisms

• Muscle Overactivity: Sustained contractions lead to secondary soft tissue changes
• Sensory Abnormalities: Altered proprioceptive processing
• Movement Patterns: Development of compensatory strategies that become pathological

Current Treatment Landscape

Oral Medications

Current pharmacological options for CBS-associated dystonia include:

Dopaminergic Agents

• Levodopa: Variable response, often disappointing
• Dopamine Agonists: Limited efficacy
• COMT Inhibitors: Adjunct benefit in some cases

Muscle Relaxants

• Baclofen: GABA-B agonist, oral and intrathecal formulations
• Benzodiazepines: Diazepam, clonazepam for muscle relaxation
• Tizanidine: Alpha-2 adrenergic agonist

Anticholinergics

• Trihexyphenidyl: May help some patients
• Benztropine: Limited role in CBS dystonia

Surgical Interventions

Deep Brain Stimulation (DBS)

• Target: Globus pallidus internus (GPi) or thalamus
• Evidence: Limited in CBS, primarily case reports
• Considerations: Cognitive decline may affect outcomes

Pallidotomy

• Less common in modern practice
• Considered when DBS not available

Botulinum Toxin Injections

Botulinum toxin has emerged as a preferred treatment for focal dystonia:

Mechanism of Action

Advantages

• Localized Effect: Targeted treatment to affected muscles
• Minimal Systemic Side Effects: Unlike oral medications
• Adjustable Dosing: Can titrate to individual response
• Reversible: Effects wear off, allowing treatment adjustment

Limitations

• Requires Skilled Injection: Anatomical precision needed
• Duration of Effect: Typically 3-4 months
• Dystonia Spread: May require multiple muscle treatment
• Antibody Formation: Some patients develop resistance

Study Objectives

Primary Endpoints

• Validated instrument for cervical dystonia
• Measures severity, disability, and pain
• Sensitive to change in clinical trials

• Adverse event monitoring
• Physical examination
• Laboratory parameters

Secondary Endpoints

• Quality of Life Measures (SF-36, PDQ-39)
• Pain Assessment (Visual Analog Scale)
• Duration of Treatment Effect
• Functional Improvement (Canadian Occupational Performance Measure)
• Patient Global Impression of Change

Exploratory Objectives

• Biomarker Studies: Exploring predictors of treatment response
• Electrophysiological Measures: Assessing motor pathway function
• Quality of Life Subscales: Detailed analysis of treatment effects

Mechanism of Action: IncobotulinumtoxinA

Molecular Mechanism

IncobotulinumtoxinA is a purified type A botulinum neurotoxin with specific properties:

Structure

• Light Chain: Zinc-dependent endopeptidase
• Heavy Chain: Mediates internalization
• No Accessory Proteins: Pure toxin complex

Pharmacodynamics

Clinical Pharmacology

• Onset of Action: 1-2 weeks post-injection
• Peak Effect: 4-6 weeks
• Duration: 12-16 weeks
• Reversibility: Full recovery by 24 weeks

Advantages Over Other Botulinum Toxins

• High Specificity: Consistent dosing
• Low Immunogenicity: Reduced antibody formation
• No Complexing Proteins: Purified formulation
• Room Temperature Stability: Simplified storage

Relevance to CBS

Unique Challenges

CBS patients present unique challenges for dystonia treatment:

Asymmetric Presentation

• Dystonia often affects one side more severely
• Requires individualized injection strategies
• May need higher doses on affected side

Progressive Nature

• Dystonia worsens as disease progresses
• May require repeated treatment cycles
• Need for long-term management plans

Cognitive Comorbidities

• May affect ability to cooperate with treatment
• Need for caregiver involvement
• Assessment challenges

Complex Phenotype

• Overlap with parkinsonism, apraxia, myoclonus
• Difficult to isolate dystonic features
• May require multiple treatment approaches

Evidence Gap

Despite the high prevalence of dystonia in CBS:

• Limited Trials: Few studies specifically in CBS population
• Off-Label Use: Botulinum toxin used without robust evidence
• Dosing Uncertainty: Optimal dosing unclear
• Outcome Measures: Need for validated endpoints

Inclusion Criteria

Disease-Specific Requirements

• Diagnosis of probable or possible CBS per established criteria
• Presence of clinically significant dystonia
• Dystonia duration ≥6 months

General Requirements

• Age 40-80 years
• Stable antiparkinsonian medications for ≥4 weeks
• Able to comply with study procedures
• Provide informed consent (or proxy consent)

Exclusion Criteria

• Previous botulinum toxin treatment within 4 months
• Active infection at injection sites
• Pregnancy or breastfeeding
• Severe comorbidities affecting safety
• Cognitive impairment precluding consent (with proxy)

Study Design

Randomized, Double-Blind Structure

The trial employs rigorous methodology:

Treatment Protocol

Injection Sites

• Pre-identified target muscles based on clinical examination
• Standardized dosing per muscle group
• Ultrasound guidance for precision

Assessment Schedule

Safety Monitoring

• Continuous adverse event collection
• Regular vital signs and examination
• Laboratory monitoring as needed
• Adverse event management protocol

Expected Outcomes

Clinical Outcomes

• Validated dosing guidelines for CBS-associated dystonia
• Evidence-based treatment algorithm for CBS dystonia
• Publication of safety profile in CBS population

Scientific Contributions

• Understanding of botulinum toxin efficacy in CBS
• Identification of prognostic factors
• Development of outcome measures specific to CBS

Future Directions

• Phase 3 trial design based on Phase 2 results
• Combination therapy protocols
• Long-term treatment strategies

Comparative Effectiveness

Against Oral Medications

Botulinum toxin offers advantages over oral medications:

• Targeted Action: Direct muscle effect vs. systemic
• Lower Side Effect Profile: Avoids sedation, confusion
• Better Tolerability: Particularly in elderly patients
• Improved Adherence: Infrequent dosing

Against Surgical Options

Compared to DBS:

• Less Invasive: No surgery required
• Reversible: No permanent alteration
• Lower Risk: Avoids surgical complications
• Accessible: Can be administered in office setting

Health Economics Considerations

Cost-Effectiveness

• Reduced hospitalizations for dystonia complications
• Improved productivity and quality of life
• Lower overall healthcare resource utilization

Quality of Life Impact

• Reduced pain and disability
• Improved ability to perform activities of daily living
• Decreased caregiver burden

See Also

• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide)
• [Dystonia in Neurodegenerative Diseases](/mechanisms/dystonia-neurodegeneration)
• [Botulinum Toxin Treatments](/therapeutics/botulinum-toxin-treatments)
• [Atypical Parkinsonism](/diseases/atypical-parkinsonism)

References